ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Evidence-Based Guideline for the management of osteoporosis in men
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 277758" data-attributes="member: 13851"><p><strong>Fig. 1 | Improvements in BMD with antiosteoporosis medications.</strong> The figure provides a representation of the percentage improvement of total hip bone mineral density (BMD) with use of anti-osteoporosis medications including alendronate, risedronate, zoledronate, ibandronate,denosumab, abaloparatide and romosozumab28.Thresholds for benefit (surrogate threshold effect(STE))65,66 for fracture, depicted as horizontal lines on the graph, are 3.18% for hip fracture, 2.13% for non-vertebral fracture, 1.83% for all fractures and1.42% for vertebral fractures. These thresholds are derived from a large series of placebo-controlled trials evaluating various anti-osteoporosis agents in women with osteoporosis.</p><p>[ATTACH=full]42377[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 277758, member: 13851"] [B]Fig. 1 | Improvements in BMD with antiosteoporosis medications.[/B] The figure provides a representation of the percentage improvement of total hip bone mineral density (BMD) with use of anti-osteoporosis medications including alendronate, risedronate, zoledronate, ibandronate,denosumab, abaloparatide and romosozumab28.Thresholds for benefit (surrogate threshold effect(STE))65,66 for fracture, depicted as horizontal lines on the graph, are 3.18% for hip fracture, 2.13% for non-vertebral fracture, 1.83% for all fractures and1.42% for vertebral fractures. These thresholds are derived from a large series of placebo-controlled trials evaluating various anti-osteoporosis agents in women with osteoporosis. [ATTACH type="full"]42377[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Evidence-Based Guideline for the management of osteoporosis in men
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top